verified SJR 1,88 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Adis International Ltd

workspace_premium Q1 — Pharmacology lock Subscription

PharmacoEconomics

PharmacoEconomics is a journal indexed in SJR in Pharmacology and Public Health, Environmental and Occupational Health with an H index of 124. It has a price of 3290 €. It has an SJR impact factor of 1,88 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,88.

PharmacoEconomics focuses its scope in these topics and keywords: cost, model, treatment, effectiveness, patients, healthcare, economic, development, review, hivinfected, ...

ISSN: 1170-7690

Publisher: Adis International Ltd

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,88 Q1

H-index 124

Acceptance rate pie_chart

24% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.290 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,88

H-index

124

Docs (year)

119

Docs 3y

324

Total refs

6440

Cites 3y

1535

Citable 3y

291

Cites/Doc 2y

4.08

Ref/Doc

54.12

Immediate OA

3290 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Avoiding Double-Counting in Pharmacoeconomic Studies

Willingness to Pay for a QALY

Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications

Cost Analysis of 2 Empiric Antibacterial Regimens Containing Glycopeptides for the Treatment of Febrile Neutropenia in Patients with Acute Leukaemia

Contributors

Consistently Estimating Absolute Risk Difference when Translating Evidence to Jurisdictions of Interest

Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis

Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care

Comparing Methods of Data Synthesis

Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era

Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment

SHOW MORE ARTICLES

Bernard S. Bloom, PhD

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models

Authors' Reply to Gandjour: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines"

Antibiotic-Associated Diarrhoea

Advances in Cancer Therapeutics and Patient Access to New Drugs

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis

Accounting for Tastes

A Review of the Pharmacoeconomics of Pharmaceutical Care

A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection

A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice

A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy

FAQs

PharmacoEconomics has an SJR of 1,88 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3290 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for PharmacoEconomics is 24%.

PharmacoEconomics

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of PharmacoEconomics?

What is the APC / publication cost?

What is the acceptance rate?